stockrow
Saturday 7 November 2026
Export SPTX’s income statement to Excel — free account
Seaport Therapeutics, Inc
SPTX Healthcare Biotechnology
- EPS
- +94.8%
- Free cash flow
- −43.8%
Quarter to September 2026, against a year earlier
21.18
0.79
+3.87%
Follow SPTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+4 more quarters Free account |
17.46 | 13.24 | 18.00 | 17.48 |
Net Debt/EBITDA |
7.91 | 6.66 | 4.15 | 9.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.10 | 0.79 | 0.42 | 0.86 | |
Capex/Depreciation |
0.24 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(11.23) | (8.21) | (0.74) | (0.42) | |
Cash per Share |
90.98 | 74.33 | 7.76 | 5.43 | |
Shareholders Equity per Share |
98.06 | 85.36 | 11.99 | 7.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
98.06 | 85.36 | 11.99 | 7.42 | |
Free Cash Flow |
(26.67) | (20.17) | (26.14) | (22.68) | |
Working Capital |
210.45 | 174.12 | 266.50 | 281.96 | |
Capital Expenditures |
(0.02) | — | — | — | |
Net Current Asset Value |
207.00 | 170.38 | 263.10 | 278.89 | |
| Other line items | |||||
Quick Ratio |
16.90 | 12.84 | 17.44 | 16.98 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(11.22) | (8.21) | (0.74) | (0.42) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | — | — | 5.27 | |
Average Assets |
— | 271.73 | 220.84 | 366.70 | |
Average Common Equity |
— | — | — | 186.30 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates · fundamentals updated 5 Nov 2026